At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 28 enrolled
Drug / intervention
VRC07-523LSbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of VRC-HIVMAB075-00-AB (VRC07-523LS) in the Sera and Mucosae of Healthy, HIV-1-Uninfected Adult Participants
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Nov 8, 2018·Updated Jun 5, 2025
In Brief
A Phase 1 clinical trial evaluating VRC07-523LS for HIV Infections. Completed, enrolled 28 participants across 2 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and pharmacokinetics of a human monoclonal antibody (VRC07-523LS) in the sera and mucosae of healthy, HIV-uninfected adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartJan 2019
Primary CompletionDec 2020
TodayJul 2026
First PostedNov 8, 2018
Enrollment StartJan 18, 2019
Primary CompletionDec 21, 2020
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 7.6 years ago
Interventions
VRC07-523LSbiological
Administered by intravenous (IV) infusion